Breaking News
0

Egalet Corp (EGLTQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Egalet is no longer active, quotes are not updating
0.01 0.00    0.00%
01/02 - Closed. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US28226B1044 
S/N: 28226B104
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.01 - 0.01
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Egalet 0.01 0.00 0.00%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

EGLTQ Overview

 
This is the main Egalet Corp stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close0.01
Day's Range0.01 - 0.01
Revenue29.65M
Open0.01
52 wk Range0.01 - 0.95
EPS - 1.38
VolumeN/A
Market Cap468.37K
Dividend (Yield)N/A (N/A)
Average Vol. (3m)589,437
P/E RatioN/A
Beta5.63
1-Year Change - 50%
Shares Outstanding56,772,101
Next Earnings DateN/A
What is your sentiment on Egalet?
or
Market is currently closed. Voting is open during market hours.

Egalet Corp News


Egalet Corp Analysis


Harry Boxer
4 Stocks To Watch: EXAS, NOVN, AAP, GIII By Harry Boxer - Oct 18, 2016

It was another sloppy day on Wall Street and an ugly way to start the week. EXACT Sciences Corporation (NASDAQ:EXAS) had a big day on Monday. I really like the way it consolidated....

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell
Technical Indicators - Neutral Neutral Neutral Strong Sell
Summary Sell Sell Sell Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Completed Patterns
Bullish doji Star 1M 2 Dec 18
Tri-Star Bullish 1W 7 Dec 02, 2018
Dragonfly Doji 1W 9 Nov 18, 2018
Stick Sandwich 1W 15 Oct 07, 2018
On Neck Bearish 1W 22 Aug 19, 2018

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 265.76 265.78 263.01 +3.12 +1.19% 25.09M 15/11  
  Alphabet A 1,333.54 1,333.54 1,311.89 +24.39 +1.86% 1.96M 15/11  
  Facebook 195.10 195.30 193.38 +1.95 +1.01% 11.53M 15/11  
  Exxon Mobil 69.19 69.30 68.67 +0.69 +1.01% 11.25M 15/11  
  Hylete 0.00 0.00 0.00 0.00 0.00% 0 29/11  
  IBM 134.40 135.12 134.03 +0.40 +0.30% 3.26M 15/11  
  Amazon.com 1,739.49 1,761.68 1,732.86 -15.11 -0.86% 3.93M 15/11  
  Uber Tech 26.79 26.80 25.96 +0.80 +3.08% 41.37M 15/11  
  Tesla 352.17 352.80 348.36 +2.82 +0.81% 4.81M 15/11  
  Macy’s Inc 16.85 17.01 16.39 +0.61 +3.76% 17.39M 15/11  

Egalet Corp Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

131

Equity Type

ORD

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
Securities Investor Protection Corporation (United States) $0 Start Trading
National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States) $500 Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EGLTQ Comments

Write your thoughts about Egalet Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
David Alexander Peterson
David Alexander Peterson Oct 09, 2016 8:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Egalet (NASDAQ: EGLT) came public in 2014 and has a market capitalization of just $200 million at the moment. Its primary drug candidate is an abuse resistant pain compound called ARYMO ER that has an October 14th PDUFA date. Approval is highly likely as ARYMO ER was recommended for approval in early August by its Ad Comm panel by an 18 to 1 vote. The shares could also be helped this week as Pain Therapeutics’ (NASDAQ: PTIE) application for pain management drug Remoxy ER was rejected by the FDA which cratered its stock and might have investors looking for alternatives in the space. The stock of Egalet sells for just under $8 a share currently. Cantor Fitzgerald reiterated a Buy rating and $21 price target on the shares earlier in September.
AkAA KAAA
AkAA KAAA Oct 09, 2016 8:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1.60 on july6
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email